Hepatocyte Growth Factor Levels in Gastric Cancer Patients
Author Information
Author(s): T Taniguchi, M Kitamura, K Arai, Y Iwasaki, Y Yamamoto, A Igari, M Toil
Primary Institution: Tokyo Metropolitan Komagome Hospital
Hypothesis
The study investigates the significance of serum hepatocyte growth factor (HGF) levels as a tumor marker in gastric cancer patients.
Conclusion
Elevated serum HGF levels are associated with tumor progression in gastric cancer, suggesting its potential as a tumor marker.
Supporting Evidence
- Serum HGF levels were significantly higher in patients with recurrent gastric cancer compared to healthy controls.
- 33.7% of primary gastric cancer patients showed elevated HGF levels.
- HGF levels were significantly associated with the degree of histological tumor invasion.
- 14 out of 15 patients with recurrent gastric cancer exhibited elevated HGF levels.
Takeaway
This study found that many gastric cancer patients have higher levels of a substance called HGF in their blood, which might help doctors understand how advanced the cancer is.
Methodology
Serum HGF levels were measured using an enzyme-linked immunosorbent assay (ELISA) in patients with primary and recurrent gastric cancer, compared to healthy controls.
Limitations
The study did not examine intratumoral HGF concentrations in gastric cancer tissues.
Participant Demographics
104 patients with primary gastric cancer (74 men, 30 women) and 15 patients with recurrent gastric cancer, average age 64.0 years; 89 healthy controls (47 men, 42 women), average age 49.7 years.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website